Is Guanfacine a psychotropic drug?

Although Guanfacine is widely used to treat mental and behavioral diseases such as attention deficit hyperactivity disorder (ADHD), anxiety disorders, tic disorders, etc., from the perspective of strict drug classification, it does not fall within the scope of typical "psychiatric drugs" or "narcotic drugs" control. According to the drug classification standards of the State Food and Drug Administration of China and the U.S. Food and Drug Administration (FDA) and DEA, guanfacine is not classified as an addictive or highly dependent drug, nor is it a controlled substance (Controlled Substance). This feature is an important advantage over central stimulants such as methylphenidate and dextroamphetamine, which are classified as Class I psychotropic drugs in China and require strict management and use with specific prescriptions.

Guanfacine has low abuse potential and low risk of addiction and acts primarily onα2A-adrenergic receptors rather than the dopamine system, so it does not cause euphoria or psychological dependence. However, although it is not controlled by psychotropic drugs, its clinical use still requires a doctor's prescription and regular follow-up to evaluate the efficacy and adverse reactions. Especially in children and adolescents, dosage adjustment needs to be done with caution as its antihypertensive side effects may cause dizziness, fatigue, low blood pressure and other problems.

In China, although guanfacine has not yet been launched on a large scale, some patients may obtain it through overseas prescription channels, such as the US version of Intuniv extended-release tablets. Doctors still need to follow drug safety management regulations when instructing patients to use it, especially paying attention to its possible synergistic effects with other antihypertensive drugs or sedatives.

Generally speaking, although guanfacine is a drug for treating mental and behavioral diseases, it is not included in the scope of psychotropic drugs or anesthetic drugs at the pharmaceutical regulatory level. Its management is relatively loose, but its clinical use still needs to be rigorous and standardized, and indications and individual differences must be fully evaluated.

Reference materials:https://go.drugbank.com/drugs/DB01018